Other Information.
−Removed: Fourth Amended and Restated Certificate of Incorporation of Kymera Therapeutics, Inc.
−Removed: (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 25, 2020).
−Removed: Second Amended and Restated Bylaws of Kymera Therapeutics, Inc.
−Removed: (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 25, 2020).
−Removed: Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No.
−Removed: 333-240264) filed with the Securities and Exchange Commission on August 17, 2020).
−Removed: Second Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its stockholders, effective as of March 11, 2020 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No.
−Removed: 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).
−Removed: Amended and Restated 2020 Employee Stock Purchase Plan.
−Removed: First Amendment to Collaboration Agreement between the Registrant and GlaxoSmithKline Intellectual Property Development Limited, dated as of August 27, 2020.
−Removed: First Amendment to Master Collaboration Agreement between the Registrant and Vertex Pharmaceuticals Incorporated, dated as of August 27, 2020.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
12 unchanged sentences
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.
−Removed: Indicates a management contract or any compensatory plan, contract or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Kymera Therapeutics, Inc.
−Removed: November 5, 2020
/s/ Nello Mainolfi, Ph.D.
1 unchanged sentence
President and Chief Executive Officer
−Removed: November 5, 2020
/s/ Bruce Jacobs, CFA, MBA
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.